Edwards Lifesciences (NYSE:EW) Issues Q4 2024 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its fourth quarter 2024 earnings guidance on Thursday. The company provided EPS guidance of 0.530-0.570 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Edwards Lifesciences also updated its FY 2024 guidance to EPS.

Edwards Lifesciences Stock Down 1.4 %

Shares of EW stock traded down $0.97 during mid-day trading on Friday, hitting $69.38. The stock had a trading volume of 8,171,656 shares, compared to its average volume of 4,595,216. The firm has a market capitalization of $41.81 billion, a P/E ratio of 29.91, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The firm’s 50-day moving average is $68.08 and its two-hundred day moving average is $78.65.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the prior year, the business earned $0.59 EPS. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences will post 2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on EW shares. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research report on Wednesday, July 31st. Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $105.00 to $75.00 in a research note on Thursday, July 25th. TD Cowen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday. Finally, Truist Financial decreased their target price on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research report on Friday. Fifteen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $75.67.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,099,238 over the last quarter. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.